论文信息 - Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report. - 字舞流文

Long response to immune checkpoint inhibitors in metastatic NSCLC despite EGFR germline mutation. A case report.

I. Bièche | C. Callens | S. Melaabi | L. Zemoura | Marion Gauthier Villars | Nicolas Girard | O. Trabelsi Grati | Catherine Daniel | Caroline Nhy | N. Girard

[1] K. Politi,et al. Anti–PD-L1 and anti-CD73 combination therapy promotes T cell response to EGFR-mutated NSCLC , 2022, JCI insight.

[2] Wenzhou Zhang,et al. Dramatic response to immunotherapy in an epidermal growth factor receptor-mutant non-small cell lung cancer: A case report , 2021, World journal of clinical cases.

[3] G. Barnett,et al. Impact of KRAS mutation status on the efficacy of immunotherapy in lung cancer brain metastases , 2021, Scientific Reports.

[4] V. Gebski,et al. Clinical and Molecular Characteristics Associated With Survival Among Patients Treated With Checkpoint Inhibitors for Advanced Non–Small Cell Lung Carcinoma: A Systematic Review and Meta-analysis , 2017, JAMA oncology.